OUR PLATFORMS
Rooted in decades of experience in molecular biology, deep understandings of molecular diagnostics, and a wide range of OMICs technologies, Complete Omics has been working with world’s leaders in cancer proteomics and cancer genomics. Throughout the past decade, Complete Omics has established several robust platforms meeting the most demanding yet critical needs from basic research and clinical applications. We are well equipped to help you with your projects through our following patented or proprietary platforms:
Genomics
Patented DEEPER-Seq Platform — the world’s only barcoded single-strand library PLUS dual-RNA probe capture approach
Proteomics
Patented MT-SRM, SAFE-SRM, MANA-SRM, Neo-True Platforms — world’s leading authority in quantitative proteomics
Metabolomics
Proprietary MetaBoost chemical derivatizations for extremely sensitive detection and quantification of small molecules.
Please click on each specific technology above to learn more about Complete Omics’ expertise and our vision in clinical applications…
PIONEERING IN MULTI-OMICS CANCER DIAGNOSTICS SINCE 2010
In 2010, Dr. Qing Wang reported the 1st pipeline for detecting mutant proteins as cancer-specific biomarkers through Mass Spectrometry following NGS (next-generation sequencing)-based identification of personalized mutations (PNAS). Throughout the past 10 years, we have been pioneering the developments of clinical multi-omics technologies including the 1st clinical proteomics-based ovarian cancer diagnostic platform (PNAS), the 1st personalized cancer neoantigen therapeutic target detection and quantification platform (Science; Science Immunology; Science Advances), the most in-depth plasma proteomics pipeline (quantifying 4,550 proteins in plasma), the world’s only dual-RNA probe-based targeted NGS pipeline (DEEPER-Seq), etc. Backed by top publication records, we are looking for active clinical collaborators to test our clinical platforms. Any clinical project is welcome if it is addressing a pressing clinical need. BTW, Collaborations are Completely FREE! Just ask.
Milestone! | Complete Omics Inc. Achieves CLIA, CAP Certification, and Medicare Enrollment
Oct 20, 2024 | BALTIMORE – Complete Omics Inc., a trailblazer in clinical proteomics and multi-omics molecular diagnostics, is proud to announce its recent achievement of CLIA and CAP certifications, along with enrollment in the Medicare system. These accomplishments underscore Complete Omics’ unwavering commitment to providing top-tier diagnostic solutions, grounded in excellence and reliability, and advancing patient care through accessible, state-of-the-art clinical proteomics testing services. The CLIA (Clinical Laboratory Improvement Amendments) certification sets a federally mandated standard for laboratory quality, accuracy, and compliance. Achieving this certification confirms Complete Omics’ ability to deliver consistent, high-quality diagnostic results that healthcare providers and patients can trust. Adding to this achievement, the CAP (College of American Pathologists) certification is another hallmark of Complete Omics’ dedication to excellence. Recognized as the gold standard in laboratory quality assurance, CAP certification involves rigorous inspections and assessments, ensuring that our laboratory adheres to the highest standards in pathology and laboratory medicine. Together, these certifications validate our ongoing commitment to clinical integrity, reliability, and patient safety. Enrollment in the Medicare system further broadens access to Complete Omics’ advanced diagnostics, making our cutting-edge proteomics-based testing solutions available to Medicare beneficiaries. With this inclusion, Complete Omics is poised to bring critical insights for early disease detection and personalized treatment to a larger population, reinforcing its mission to make precision diagnostics a standard in modern healthcare. “Our CLIA and CAP certifications, along with Medicare enrollment, mark significant milestones for Complete Omics as we expand our reach and impact in the clinical diagnostics field,” said Qing Wang, Founder and CEO of Complete Omics Inc. “We are dedicated to providing healthcare professionals and patients with reliable, high-quality diagnostic services that empower precise healthcare decisions and foster improved patient outcomes.” Complete Omics Inc. remains committed to innovation and quality in clinical proteomics and multi-omics blood tests, setting new benchmarks in diagnostic technology and accessibility.
Strategic Partnership with M20 Genomics, Advancing Single-Cell Multi-Omics for Precision Medicine
August 20, 2024 | BALTIMORE – Complete Omics is thrilled to announce an electrifying partnership with M20 Genomics, a trailblazer in single-cell and spatial transcriptomics! Together, these industry leaders are embarking on a groundbreaking collaboration set to redefine the landscape of single-cell multi-omics. By merging their cutting-edge technologies, this dynamic alliance is poised to revolutionize disease research and precision medicine, pushing the boundaries of what’s possible in healthcare innovation.
Exciting News | Valid-NEO® Platform Secures U.S. Patent
May 12, 2024 | BALTIMORE – Complete Omics is thrilled to announce that our Valid-NEO® platform’s “Method and System for Neoantigen Analysis” has been granted a U.S. patent after a rigorous three-year review by the USPTO. This breakthrough makes Valid-NEO® the only patented method in the U.S. capable of directly quantifying neoantigens on cell surfaces. This milestone underscores the platform’s significant technical value, setting it apart in the neoantigen detection field. Valid-NEO® has revolutionized the market with its ability to overcome traditional challenges in cancer-related gene mutation analysis. By directly and accurately detecting neoantigens with high sensitivity and specificity, Valid-NEO® allows for absolute quantification and precise analysis at the single-cell level, requiring minimal sample amounts. This makes it a game-changer in personalized medicine and drug development, offering unparalleled accuracy in identifying neoantigen sequences and their immunogenicity. In practice, Valid-NEO® supports both innovative drug development and companion diagnostics, helping pharmaceutical companies identify patients suitable for clinical trials and aiding in personalized treatment planning. Unlike traditional gene sequencing combined with AI algorithms, Valid-NEO® offers superior sensitivity by directly reading data from cell surfaces, making it a core technology in identifying tumor neoantigen targets and enhancing cancer immunotherapy. We are immensely proud of this achievement and its implications for the future of cancer treatment. Valid-NEO® not only advances neoantigen detection but also deepens the application of personalized medicine in oncology. We believe this patented technology will drive the development of new drugs and therapies targeting tumor neoantigens, accelerating the realization of more universal personalized cancer immunotherapy solutions. For detailed case studies on Valid-NEO® applications, please refer to our publications: “Targeting a neoantigen derived from a common TP53 mutation,” Science, 2021. “Bispecific antibodies targeting mutant RAS neoantigens,” Science Immunology, 2021. “Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy,” Science Advances, 2022.
“We see each individual as an integrity of multiple universes. We are striving to provide the most sensitive and specific health surveillance tests through measuring the individual’s different pools of biological molecules simutaneously.”
— Qing Wang, Founder and CEO
Our People | check here for the team of Complete Omics |
Complete Omics is incorporated by a vibrant team of excellent scientists. With decades of expertises in molecular diagnostics and Omics-based technologies, our scientists and directors are building something fantastic for human population. We are hiking alone, but are determined to change the world!
-
Hui Zhang
CSO and Director for Center of Advanced Proteomics -
Naseruddin Höti
Medical Director -
Morgan Fair
Molecular Diagnostic Scientist -
Raghothama Chaerkady
VP for Proteomics
2023–Closing latest financing round with QiMing Venture Partners
Complete Omics proudly announces its latest financing round’s success, significantly backed by Qiming Venture Partners, China’s top healthcare VC. This achievement is particularly remarkable given the current economic climate, where securing investment has become increasingly challenging, especially in the healthcare and pharmaceutical sectors. Our team’s dedication and resilience have been key in reaching this pivotal moment for our company. Our collaboration with Qiming, known for investing in industry leaders like Xiaomi (1810.HK), Meituan (3690.HK), and Bilibili (BILI), signals strong confidence in our mission and future. This investment propels us into new realms of innovation in clinical proteomics and molecular diagnostics, underscoring our commitment to transforming healthcare. It positions us among influential firms, promising a future of growth and breakthroughs despite the economic slowdown. We’re excited for what’s ahead and invite our community to join us in this journey towards significant healthcare advancements. Together, we’re poised to redefine the landscape of personalized medicine. (Ref. 1, 2).A Proud Partner of QiMing VC
Latest News
Milestone! | Complete Omics Inc. Achieves CLIA, CAP Certification, and Medicare Enrollment
Oct 20, 2024 | BALTIMORE – Complete Omics Inc., a trailblazer in clinical proteomics and multi-omics molecular diagnostics, is proud to announce its recent achievement of CLIA and CAP certifications,…
Strategic Partnership with M20 Genomics, Advancing Single-Cell Multi-Omics for Precision Medicine
August 20, 2024 | BALTIMORE – Complete Omics is thrilled to announce an electrifying partnership with M20 Genomics, a trailblazer in single-cell and spatial transcriptomics! Together, these industry leaders are…
Exciting News | Valid-NEO® Platform Secures U.S. Patent
May 12, 2024 | BALTIMORE – Complete Omics is thrilled to announce that our Valid-NEO® platform’s “Method and System for Neoantigen Analysis” has been granted a U.S. patent after a rigorous…